| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.2 | -13.6 |
| EPS (diluted, $ a share) | $-0.62 | $-2.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TIL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Instil Bio, Inc.: key numbers
- Share price
- $5.75Close, Nov 16
- Market cap
- $39M
- Shares outstanding
- 6.78MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Instil Bio, Inc.
All →Instil Bio Financial Results
Instil Bio reported third quarter 2026 financial results, highlighting a cash position of $67.1 million which is expected to fund operations through 2027. The company is transitioning to an asset-focused development model through subsidiaries while reporting a significantly narrowed net loss compared to the prior year period.
- Term
- Q3 2026